Novel IHC Antibodies from Cell Marque

Why use the CD56 & PAX-8 antibodies from Cell Marque?

Why was the CD56 antibody recognized by NordiQC?

Why is PAX-8 one of the most used antibodies world wide?

We tell you why.

CD56, recognized by NordiQC

CD56, known as neural cell adhesion molecule, was originally identified in the nervous system and belongs to a group of cell adhesion molecules including cadherns, selectins, and integrins. Anti-CD56 recognizes two proteins of the neural cell adhesion molecule, the basic molecule expressed on most neuroectodermally-derived cell lines, tissues and neoplasms (e.g. neuroblastomas, small cell carcinomas). It is also expressed on some mesodermally derived tumors (Rhabdomyosarcoma). Furthermore, CD56 has found great utility in the recognition of natural killers and NK/T-cell lymphomas; 71% of myelomas are positive; higher sensitivity in diagnosis of small cell carcinoma than chromogranin and synaptophysin. Light staining of smooth muscle elements may be seen.

CD56

Features CD56 antibody:

  • Clone: MRQ-42
  • Positively stains Natural killer cells (far superior from previous clones)
  • Positive in Neuroendocrine tumors
  • Used for the identification of NK/T-cell lymphomas and leukemias
  • Positive in small cell carcinoma

Available formats & ordering information about CD56 antibody:

0.1 ml concentrated, Cat.# 156R-94
0.5 ml concentrated, Cat.# 156R-95
1 ml concentrated, Cat.# 156R-96
1 ml prediluted, Cat.# 156R-97
7 ml prediluted, Cat.# 156R-98
5 Positive Control Slides, Cat.# 156S

PAX-8, one of the most popular Cell Marque antibodies world wide

This protein is a member of the paired box (PAX) family of transcription factors. Members of this gene family typically encode proteins which contain a paired box domain, an octapeptide, and a paired-type homeodomain. This nuclear protein is involved in thyroid follicular cell development and expression of thyroid-specific genes. Mutations in this gene have been associated with thyroid dysgenesis, thyroid follicular carcinomas and atypical thyroid adenomas.

PAX-8 is expressed in the thyroid (and associated carcinomas), non-ciliated mucosal cells of the fallopian tubes and simple ovarian inclusion cysts, but not normal ovarian surface epithelial cells. PAX-8 is expressed in a high percentage of ovarian serous, endometrioid, and clear cell carcinomas, but only rarely in primary ovarian mucinous adenocarcinomas. Studies have also found PAX-8 experession in renal tubules as well as renal carcinoma, nephroblastoma and seminoma. Normal lung and lung carcinomas do not express PAX-8. Similarly, the absence of expression of PAX-8 in breast and other non-GYN carcinomas other than those primary to the thyroid indicates that PAX-8 is an important new marker of ovarian cancer and a useful marker for the differential diagnoses in lung and neck tumors, or tumors at distant sites where primary lung carcinoma or thyroid carcinoma are possibilities. PAX-8, combined with organ system-specific markers such as uroplakin, mammaglobin, and TTF-1 can be a very useful panel to determine the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast.
PAX-8

Features PAX-8 antibody:

• Clone: Polyclonal
• Visualization: Nuclear
• Ovarian Carcinoma (high sensitivity for serous ca)
• Thyroid transcription factor
• Kidney metastasis (85%)
• Multiple applications
• USCAP 2010, IAP 2010

Available formats and ordering information about PAX-8 antibody:

0.1 ml concentrated, Cat.# 363A-14
0.5 ml concentrated, Cat.# 363A-15
1 ml prediluted, Cat.# 363A-17
7 ml prediluted, Cat.# 363A-18
5 Positive Control Slides, Cat.# 363S

More novel antibodies

Cell Marque on YOU TUBE:

Pretreatment and Immunostaining Procedures

Manual IHC Staining

Hier Protocol

Contact us by e-mail, phone or chat to discover the complete novel antibody list from Cell Marque. Our IHC product specialists are pleased to tell you everything you need to know.

 

35 years

We use cookies to ensure that we give you the best experience on our website. More information

Accept